PRKCH — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Balanol (SCHEMBL62128)	1.00	17/20
Balanol (SCHEMBL62129)	1.00	17/20
Ucn-01 (SCHEMBL259162)	1.00	11/20
Staurosporine (SCHEMBL8156)	1.00	9/20
Staurosporine (SCHEMBL8157)	1.00	9/20
SCHEMBL272173	0.75	7/20
SCHEMBL117745	0.56	7/20
SCHEMBL115053	0.56	6/20
Fasudil (SCHEMBL4674)	1.00	5/20
Phorbol Myristate Acetate (SCHEMBL115567)	1.00	5/20
SCHEMBL162855	1.00	5/20
SCHEMBL190590	1.00	5/20
SCHEMBL9306	0.89	5/20
SCHEMBL260178	0.81	5/20
SCHEMBL258513	0.79	5/20
SCHEMBL190415	0.63	5/20
SCHEMBL78989	0.62	5/20
Phorbol (SCHEMBL72895)	0.62	5/20
SCHEMBL190414	0.62	5/20
SCHEMBL224940	0.56	5/20

Clinical trials — most relevant to PRKCH by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
Signaling Mechanisms and Vascular Function in Diabetes Mellitus	PHASE2/PHASE3	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML	PHASE2	COMPLETED
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients	PHASE2	COMPLETED
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas	PHASE1	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.	nan	NOT_YET_RECRUITING
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Fat Induced Insulin Resistance and Atherosclerosis	nan	COMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH	nan	COMPLETED
Glucagon Like Peptide-1 in Remote Ischemic Conditioning	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PRKCH binder may also engage these)

Protein	Name	Similarity
Q64617	—	1.000	Q64617 →
P23298	—	1.000	P23298 →
P34885	—	1.000	P34885 →
P13678	—	1.000	P13678 →
PRKCE	Protein kinase C epsilon type	0.995	landscape →
Q16975	—	0.995	Q16975 →
PRKCD	Protein kinase C delta type	0.995	landscape →
P09215	—	0.994	P09215 →
P10830	—	0.994	P10830 →
Q5PU49	—	0.993	Q5PU49 →
P09216	—	0.993	P09216 →
P16054	—	0.993	P16054 →
Q02111	—	0.992	Q02111 →
Q16974	—	0.991	Q16974 →
PRKCA	Protein kinase C alpha type	0.990	landscape →
P05128	—	0.990	P05128 →
P05130	—	0.989	P05130 →
P13677	—	0.989	P13677 →
PRKCB	Protein kinase C beta type	0.989	landscape →
P63318	—	0.988	P63318 →
P63319	—	0.988	P63319 →
PRKCQ	Protein kinase C theta type	0.988	landscape →
P10102	—	0.988	P10102 →
Q6PFQ0	—	0.987	Q6PFQ0 →
P05696	—	0.987	P05696 →
Q25378	—	0.987	Q25378 →
A8KBH6	—	0.987	A8KBH6 →
Q4R4U2	—	0.987	Q4R4U2 →
P10829	—	0.987	P10829 →
P34722	—	0.987	P34722 →